KRAS and cancer: By upregulating these enzymes, mutant KRAS triggers the shunting of glycolytic intermediates into the hexosamine biosynthesis pathway (HBP) to generate UDP-N-acetylglucosamine (UDP-GlcNAc) for glycoprotein, glycolipid, proteoglycan, and glycosylphosphatidylinositol anchor biosynthesis in cancer cells [5, 19].